Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial  Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through anticipated clinical readout for BBI-355 and key development milestones for third ecDTx program Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, stepping down; James L. Freddo, M.D., to serve as Interim Chief Medical Officer SAN DIEGO, Dec. 12 ...